Revenue segments as reported by the company.

Transcatheter Aortic Valve Replacement

Transcatheter Mitral and Tricuspid Therapies

Surgical Structural Heart

Critical Care

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative expenses

Research and development expenses

Intellectual property litigation expenses, net

Change in fair value of contingent consideration liabilities

Special charges

Restructuring expenses

Other operating expenses, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Edwards Lifesciences

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring systems measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Edwards Lifesciences projects robust sales growth amidst market advancements

Edwards Lifesciences showcased strong sales growth and financial performance in Q4 2022. Despite challenges like FX impacts and spotty backlog, the company remains confident in its growth outlook. Encouraging opportunities lie in TMTT and Surgical Structural Heart segments for future expansion.

Edwards Lifesciences reports robust Q1 sales, eyes global expansion

Edwards Lifesciences delivered strong sales performance in Q1, driven by key product segments and global growth.
The company faces challenges in managing expenses and navigating competitive dynamics, particularly in Japan.
Opportunities lie in continued market growth, product innovation, and efficiency enhancements across operations.
Overall, Edwards Lifesciences remains well-positioned for growth and market leadership in the cardiovascular space.

Edwards Lifesciences exceeds Q2 expectations, raises full-year guidance

Edwards Lifesciences delivered strong Q2 results, raising full year guidance and highlighting growth in key segments. While facing challenges like seasonal impacts and market recovery issues, the company remains focused on innovation and market expansion.

Edwards Lifesciences excels in Q3, poised for diversified growth

Edwards Lifesciences delivered a strong Q3 performance with growth across key segments and a positive outlook for 2023.
The company's focus on innovation, differentiated sales strategies, and patient-centric initiatives position it well for future growth.
Challenges in pricing dynamics and market competition require strategic management, while opportunities in diverse therapies and patient activation initiatives offer avenues for expansion.
Overall, Edwards Lifesciences maintains a solid financial position, supported by a robust balance sheet and a commitment to long-term growth.

Edwards Lifesciences posts strong Q4 results, eyes global growth opportunities

Edwards Lifesciences' Q4 2023 performance reflects solid financial health and strategic investments for future growth. Despite facing challenges such as rising expenses and competitive pressures, the company is well-positioned to capitalize on opportunities through innovation and market expansion.

Edwards Lifesciences reports robust Q1 sales growth and outlook

Edwards Lifesciences shows strong sales growth across key segments and raises 2024 outlook.
Investments in transcatheter platforms and positive milestones drive sustainable growth.
Challenges include managing increased expenses and ensuring center readiness for new therapies.
Opportunities in AI implementation, patient care initiatives, and diversified growth potential.

Edwards Lifesciences reports strong Q3 performance and strategic growth focus

Edwards Lifesciences delivered robust Q3 results driven by TAVR and TMTT growth, showcasing resilience and innovation.
While facing challenges in certain markets like Japan, Edwards maintains a strong competitive position and strategic focus on long-term growth.
The company's acquisitions, product advancements, and maintained guidance reflect a commitment to expansion and market leadership.
With opportunities in innovation and global expansion, Edwards is poised for continued growth and success in the medical technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

HCA Healthcare

Labcorp Holdings Inc

Insulet

Universal Health Services

We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.

5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings

Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards L.

Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024

The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.

Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?

Integer Holdings

Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Edwards Lifesciences (EW). But which of these two companies is the best option for those looking for undervalued stocks?

ITGR vs. EW: Which Stock Should Value Investors Buy Now?

DexCom

STERIS

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth.

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

Amgen

Ascendis Pharma

Cytokinetics

Tema Obesity & Cardiometabolic ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

Eli Lilly

Medtronic

Novo Nordisk

SPDR S&P 500 ETF Trust

Viking Therapeutics

Vertex Pharmaceuticals

Health Care Select Sector SPDR Fund

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

ATLANTA--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families. The findings of this study, which identified a significant discrepancy between participant self-awareness and actual prevalence of heart disease and associated risk factors, were presented today during a late-breaking clinic.

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Here is how Edwards Lifesciences (EW) and Avinger (AVGR) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Edwards Lifesciences (EW) This Year?

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.

Edwards Lifesciences (EW) Hits 52-Week High: What's Driving It?

Artivion

Shockwave Medical

Transmedics Group Inc

We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.

Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024

Abbott Labs

iShares U.S. Medical Devices ETF

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Medical Devices ETF Hits 52-Week High: Stocks to Watch

Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.

Edwards Lifesciences' (EW) SAPIEN TAVR Study Outcome Favorable

WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. A study of Edwards' latest TAVR technology, the SAPIEN 3 Ultra RESILIA valve, found lower rates of paravalvular leak (PVL) at 30 days, lower echo-derived gradients and larger eff.

Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock?

Edwards Lifesciences (EW) Up 2% Since Last Earnings Report: Can It Continue?

With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.

Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth

Investors are optimistic about Edward Lifesciences' (EW) progress with the Structural Heart business and strong TAVR potential.

Here's Why You Should Buy Edward Lifesciences (EW) Stock Now

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessible later the same day. A.

Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference

Edwards (EW) is demonstrating the strong performance of the SAPIEN 3 Ultra valve in the United States, Europe and Rest of World.

Edwards (EW) Gains From Balanced Core Growth and New Launches

Edwards Lifesciences' (EW) Q4 revenues register year-over-year growth on its strong differentiated portfolio of advanced therapies.

Edwards Lifesciences (EW) Q4 Earnings Meet, Margins Dip

Edwards Lifesciences Corporation (EW) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Edwards Lifesciences (EW) Q4 Earnings: A Look at Key Metrics

Edwards Lifesciences (EW) came out with quarterly earnings of $0.64 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.64 per share a year ago.

Edwards Lifesciences (EW) Q4 Earnings Match Estimates

Edwards Lifesciences reported fourth-quarter profit on Tuesday that beat Wall Street estimates, helped by strong demand for the company's artificial heart valves and other devices.

News for Edwards Lifesciences Stock (EW)